Journal of Nanobiotechnology · 2022 · 14 citations · 23 references
PharmacyInfectious DiseasesPharmacologyDrug DeliveryNanoparticle Drug DeliveryPulmonary Drug DeliveryAntiviral AgentsAntiviral PharmacotherapyAntiviral TherapyDrug Delivery BiomaterialsNanomaterials For Drug DeliveryNanomedicineAntiviral TherapeuticsAntiviral TreatmentBone Marrow Mesenchymal Stem CellsBone Marrow-derived Mesenchymal Stromal CellsPh-sensitive NanoparticlesPoly(lactic-co-glycolic Acid) NanoparticlesViral Dna ReplicationViral Infection-associated Inflammation
BACKGROUND: Cytomegalovirus (CMV) pneumonia is a major cause of morbidity and mortality in immunodeficiency individuals, including transplant recipients and Acquired Immune Deficiency Syndrome patients. Antiviral drugs ganciclovir (GCV) and phosphonoformate (PFA) are first-line agents for pneumonia caused by herpesvirus infection. However, the therapy suffers from various limitations such as low efficiency, drug resistance, toxicity, and lack of specificity. METHODS: The antiviral drugs GCV and PFA were loaded into the pH-responsive nanoparticles fabricated by poly(lactic-co-glycolic acid) (PLGA) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and further coated with cell membranes derived from bone marrow mesenchymal stem cells to form artificial stem cells, namely MPDGP. We evaluated the viral suppression effects of MPDGP in vitro and in vivo. RESULTS: MPDGP showed significant inflammation tropism and efficient suppression of viral replication and virus infection-associated inflammation in the CMV-induced pneumonia model. The synergistic effects of the combination of viral DNA elongation inhibitor GCV and viral DNA polymerase inhibitor PFA on suppressing the inflammation efficiently. CONCLUSION: The present study develops a novel therapeutic intervention using artificial stem cells to deliver antiviral drugs at inflammatory sites, which shows great potential for the targeted treatment of pneumonia. To our best knowledge, we are the first to fabricate this kind of artificial stem cell to deliver antiviral drugs for pneumonia treatment.
23
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Scott G. Hansen, Julia C. Ford, Matthew S. Lewis et al. · Nature · 2011 · 993 citations · Full text